Sue Hager

About

Sue Hager is an advisory partner on the a16z Bio + Health team.

Prior to joining Andreessen Horowitz, she was chief investor relations and communications officer for Section 32 venture capital. Sue also served as chief communications officer and head of health policy and advocacy for life sciences companies including EQRx (Nasdaq: EQRx) and Foundation Medicine (acquired by Roche) where, among other initiatives in her six-year tenure, she led the company’s efforts to secure the first broad Medicare Coverage Decision for comprehensive genomic profiling in oncology. Previously she served in similar roles at companies including Bayer Healthcare, Myriant Corporation (acquired by PTT Global Chemical), Targanta (acquired by The Medicines Company) and Coley Pharmaceutical (acquired by Pfizer).

She holds a BS with honors in biology and earned her MBA from Northeastern University in Boston, MA. Sue currently serves on the Board of Directors for MassBio and the Emily Whitehead Foundation. Sue grew up in Rhode Island and returned there recently, where she enjoys boating, surfing, cycling, and hiking with her husband and their dogs.